Prevention and treatment of heterotopic ossification after spinal cord injury

Journal of Spinal Cord Medicine

Volumn 27, Issue 4, 2004, Pages 376-382

  Banovac, Kresimir ^a,b   Sherman, Andrew L ^a,b   Estores, Irene M ^a,b   Banovac, Filip ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b JACKSON MEMORIAL HOSPITAL   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C reactive protein; Creatine phosphokinase; Etidronate; Heterotopic ossification; NSAID; Prevention; Roficoxib; Spinal cord injuries

Indexed keywords

BONE MORPHOGENETIC PROTEIN; C REACTIVE PROTEIN; CREATINE KINASE; ETIDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ALGORITHM; ARTICLE; BONE SCINTISCANNING; CREATINE KINASE BLOOD LEVEL; DIAGNOSTIC VALUE; DISEASE SEVERITY; HETEROTOPIC OSSIFICATION; HUMAN; MEDICAL CARE; NONHUMAN; PROTEIN EXPRESSION; RECURRENT DISEASE; SPINAL CORD INJURY; TISSUE INJURY; TREATMENT PLANNING; DRUG COMBINATION; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG THERAPY, COMBINATION; ETIDRONIC ACID; HUMANS; OSSIFICATION, HETEROTOPIC; SPINAL CORD INJURIES;

EID: 7944229172     PISSN: 10790268     EISSN: None     Source Type: Journal    
DOI: 10.1080/10790268.2004.11753775     Document Type: Article

References (70)

1. Subbarao JV, Garrison SJ. Heterotopic ossification: diagnosis and management, current concepts and controversies. J Spinal Cord Med. 1999;22:273-283.
2. VanKuijk AA, Geurts ACH, van Kuoorvelt HJM. Neurogenic heterotopic ossification in spinal cord injury. Spinal Cord. 2002; 40:313-326.
3. Shahab D, Elgazzar AH, Collier BD. Heterotopic ossification. J Nucl Med. 2002;43:346-353.
4. Banovac K, Renfree KJ, Hornicek FJ. Heterotopic ossification after brain and spinal cord injury. Clin Rev Phys Rehabil Med. 1998;10: 223-256.
5. Yamaguchi A, Katagiri T, Ikeda T, et al. Recombinant human bone morphogenic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J Cell Biol. 1991;113: 681-687.
6. Chen D, Ji X, Harris MA, et al. Differentiational roles for bone morphogenic protein receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblasts and adipocytes lineages. J Cell Biol. 1998;142:295-305.
7. Wozney JM. The bone morphogenic protein family and osteogenesis. Mol Reprod Dev. 1992;32:160-167.
8. Bosch P, Musgrave DS, Lee JY, et al. Osteoprogenitor cells within skeletal muscle. J Orthop Res. 2000;18:933-944.
9. Gonda K, Nakaoka T, Yoshimura K, et al. Heterotopic ossification of degenerating rat skeletal muscle induced by adenovirus-mediated transfer of bone morphogenic protein 2 gene. J Bone Miner Res. 2000;15:1056-1065.
10. Nakamura Y, Wakitani S, Nakayama J, et al. Temporal and spatial expression profiles of BMP receptors and Noggin during BMP-2-induced ectopic bone formation. J Bone Miner Res. 2003;18:1854-1862.
11. Urist MR. Bone morphogenic protein: the molecularization of skeletal system development. J Bone Miner Res. 1997;12:343-346.
12. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science. 1988;242: 1528-1534.
13. Barnes GL, Kosteniuk PJ, Gerstenfeld LC, Einhorn TA. Growth factor regulation of fracture repair. J Bone Miner Res. 1999;14:1805-1815.
14. Nakase T, Nomura S, Yoshikawa H, et al. Transient and localized expression of bone morphogenic protein-4 messenger RNA during fracture healing. J Bone Miner Res. 1994;9:651-659.
15. Towler DA. Angiogenesis and marrow stromal cell fates: roles in bone strength. Osteoporos Int. 2003;14(suppl 5):S46-S53.
16. Doherty MJ, Ashton BA, Walsh S, et al. Vascular pericytes express osteogenic potential in vitro and in vivo. J Bone Miner Res. 1998;13:828-838.
17. Hardy A, Dickson J. Pathological ossification in traumatic paraplegia. J Bone Joint Surg. 1963;45B:76-87.
18. Wharton G, Morgan T. Ankylosis in the paralyzed patient. J Bone Joint Surg. 1970;52A:105-112.
19. Silver JR. Heterotopic ossification: clinical study of its possible relationship to trauma. Paraplegia. 1969;7:220-230.
20. Stover SL, Hataway CJ, Zeiger HE. Heterotopic ossification in spinal cord injury patients. Arch Phys Med Rehabil. 1976;56:199-204.
21. Rossier AB, Bussat P, Infabte F, et al. Current facts on para-osteoarthopathy (POA). Paraplegia. 1973;11:36-78.
22. Goldman J. Heterotopic ossification in spinal cord injuries. Physiotherapy. 1980;66:219-220., 1073
23. Silver JR. Heterotopic ossification. A clinical study of its possible relationship to trauma. Paraplegia. 1969;7:220-230.
24. Naraghi FF, DeCoster TA, Moneim MA, et al. Heterotopic ossification. Orthopedics. 1996;19:145-152.
25. Bodley R, Jamous A, Short D. Ultrasound in the early diagnosis of heterotopic ossification in patients with spinal injuries. Paraplegia. 1993;31:500-506.
26. Snoecx M, De Muynck M, Van Laere M. Association between muscle trauma and heterotopic ossification in spinal cord injured patients: reflections of their causal relationship and the diagnostic value of ultrasonography. Paraplegia. 1995;33:464-468.
27. Riklin C, Baumberger M, Wick L, et al. Deep vein thrombosis and heterotopic ossification in spinal cord injury: a 3 year experience at the Swiss Paraplegic Centre Nottwill. Spinal Cord. 2003;41:192-198.
28. Cassar-Pullicino VN, McClelland M, Badwan DAH, et al. Sonographic diagnosis of heterotopic bone formation in spinal injury patients. Paraplegia. 1993;31:40-50.
29. Bethroux F, Calmels P, Aigoin JL, et al. Heterotopic ossification and rhabdomyolysis. Paraplegia. 1995;33:164-166.
30. Lotta S, Scelsi L, Scelsi R. Microvascular changes in the lower extremities of paraplegics with heterotopic ossification. Spinal Cord. 2001;39:595-598.
31. Thomas EA, Cassar-Pullicino VN, McCall IW. The role of ultrasound in the early diagnosis and management of heterotopic bone formation. Clin Radiol. 1991;43:190-196.
32. Ackerman LV. Extra-osseous localized non-neoplastic bone and cartilage formation (so-called myositis ossificans). J Bone Joint Surg. 1958;40A:279-298.
33. Lenderman HP, Schweizer ME, Morrison WB. Pelvic heterotopic ossification: MR imaging characteristics. Radiology. 2002;222: 189-195.
34. Stover SL, Hahn HR, Miller JM. Disodium etidronate in the prevention of heterotopic ossification following spinal cord injury. Paraplegia. 1976;14:146-156.
35. Kjarsgaard AP, Schmidt SA. Total hip arthroplasty. The role of anti-inflammatory medication in prevention of heterotopic ossification. Clin Orthop Rel Res. 1991;263:78-86.
36. McMahon JS, Naddell JP, Matron J. Effect of short course indomethacin on heterotopic bone formation after uncemented total hip arthroplasty. J Arthroplasty. 1991;6:259-264.
37. Banovac K, Williams JM, Patrick LD, Haniff YM. Prevention of heterotopic ossification after spinal cord injury with indomethacin. Spinal Cord. 2001;39:370-374.
38. Banovac K, Williams JM, Patrick LD, Levi A. Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib). Spinal Cord. 2004.
39. Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res. 1998;47(suppl 2):578-587.
40. Orzel JA, Rudd TG. Heterotopic bone formation: clinical, laboratory, and imaging correlation. J Nucl Med. 1985;26:125-132.
41. Hsu JD, Sakimura I, Stauffer ES. Heterotopic ossification around the hip joint in spinal cord injured patients. Clin Orthop Rel Res. 1975;112:165-169.
42. Tibone J, Sakimura I, Nickel VL, Hsu JD. Heterotopic ossification around the hip spinal cord injured patients. J Bone Joint Surg. 1978; 60A:769-775.
43. Banovac K, Gonzalez F, Wade N, Bowker JD. Intravenous disodium etidronate therapy in spinal cord injury patients with heterotopic ossification. Paraplegia. 1993;31:660-666.
44. Garland DE, Orwin JF. Resection of heterotopic ossification in patients with spinal cord injuries. Clin Orthop Rel Res. 1989;242: 169-176.
45. Sherman AL, Williams JM, Patrick LD, Banovac K. The value of serum creatine kinase in early diagnosis of heterotopic ossification. J Spinal Cord Med. 2003;26:227-230.
46. Estores IM, Harrington A, Banovac K. Diagnostic value of C-reactive protein and erythrocyte sedimentation rate in spinal cord injured patients with heterotopic ossification. J Spinal Cord Med. 2004.
47. Singh RS, Craig MC, Katholi CR, et al. The predictive value of creatine phosphokinase and alkaline phosphatase in identification of heterotopic ossification in patients after spinal cord injury. Arch Phys Med Rehabil. 2003;84:1584-1588.
48. Sell S, Schleh T. C-reactive protein as an early indicator of the formation of heterotopic ossifications after total hip replacement. Arch Orthop Trauma Surg. 1999;119:205-207.
49. Banovac K, Gonzalez F. Evaluation and management of heterotopic ossification in patients with spinal cord injury. Spinal Cord. 1997; 35:158-162.
50. Finerman GA, Stover SL. Heterotopic ossification following hip replacement and spinal cord injury. Two clinical studies with EHDP. Metab Bone Dis Rel Res. 1981;4/5:337-342.
51. Garland DE, Alday B, Venos KG, Vogt JC. Diphosphonate treatment for heterotopic ossification in spinal cord inured patients. Clin Orthop Rel Res. 1983;176:197-200.
52. Freed JH, Hahn H, Menter R, Dillon T. The use of three phase bone scan in the early diagnosis of heterotopic ossification and in the evaluation of Didronel therapy. Paraplegia. 1982;20:208-216.
53. Banovac K, Gonzales F, Renfree KJ. Treatment of heterotopic ossification after spinal cord injury. J Spinal Cord Med. 1997;20: 60-65.
54. Recker RR, Saville PG. Intestinal absorption of disodium ethane-1-hydroxy-1-disphosphonate using deconvulsion technique. Toxicol Appl Pharmacol. 1973;24:580-589.
55. Nakahara N, Yoshikawa H, Tokjoaka I, Ono K. Effect of ethane-1-hydroxy-1-disphosphonate on ectopic bone formation induced by murine osteosarcoma derived bone inducing substance. Bone. 1990;7:229-233.
56. Flora L, Hassing GS, Cloyd GG, et al. The long term skeletal effects of EHDP in dogs. Metab Bone Dis. 1981;4/5:289-300.
57. Francis MD, Russell RGG, Fleisch H. Disphosphonate inhibits formation of calcium phosphate crystals in vitro and in vivo. Science. 1969;165:1964-1966.
58. Banovac K. The effect of etidronate on late development of heterotopic ossification after spinal cord injury. J Spinal Cord Med. 2000;23:40-44.
59. Hu HP. The effect of bisphosphonate on induced heterotopic bone. Clin Orthop Rel Res. 1991;272:259-267.
60. Plasmans CMT, Kuypers W, Sloff TJH. The effect of ethane-1-hydroxy-1- disphosphonatic acid on matrix induced ectopic bone formation. Clin Orthop Rel Res. 1978;132:233-242.
61. Craven PL, Urist MR. Osteogenesis by radioisotope cell populations in implants of bone matrix under the influence of ionizing radiation. Clin Orthop Rel Res. 1971;76:221-243.
62. Brady LW. Radiation induced sarcomas of bone. Skel Radiol. 1979;4:72-78.
63. Sautter-Bihl ML, Liebermeister E, Nanassy A. Radiotherapy as a local treatment option for heterotopic ossification in patients with spinal cord injury. Spinal Cord. 2000;38:33-36.
64. Meiners T, Abel R, Bohm V, Gerner HJ. Resection of heterotopic ossification of the hip in spinal cord injured patients. Spinal Cord. 1997;35:443-445.
65. Freebourn TM, Barber DB, Able AC. The treatment of immature heterotopic ossification in spinal cord injury with combination surgery, radiation therapy and NSAID. Spinal Cord. 1999;37:50-53.
66. McAuliffe JA, Wolfson AH. Early excision of heterotopic ossification about the elbow followed by radiation therapy. J Bone Joint Surg. 1997;79A:749-755.
67. Subbarao YV, Nemchausky BA, Gratzer M, et al. Resection or heterotopic ossification and Didronel therapy-regaining wheelchair independence in the spinal cord injured patients. J Am Paraplegia Soc. 1987;10:3-7.
68. Stover SL, Nieman KMW, Tullos J. Experience with surgical resection of heterotopic bone in spinal cord injured patients. Clin Orthop Rel Res. 1991;263:71-77.
69. Jamil F, Subbarao JV, Banovac K, et al. Management of immature heterotopic ossification of the hip. Spinal Cord. 2002;40:388-395.
70. Garland DE. Clinical observations on fractures and heterotopic ossification in the spinal cord and traumatic brain injured populations. Clin Orthop Rel Res. 1988;178:86-101.